Core Viewpoint - 舶望制药 is considering an IPO in Hong Kong, aiming to raise approximately $300 million, potentially becoming the largest biopharmaceutical IPO in Hong Kong since 2024, aside from 恒瑞医药 [1] Company Overview - 舶望制药 is a clinical-stage biotechnology company focused on developing next-generation siRNA drugs to provide better treatment options for global patients [1] - The company utilizes its industry-leading RADS platform technology, which offers enhanced activity, durability, and safety in RNA molecules, to establish a diverse pipeline of siRNA candidates [1] Product Pipeline - 舶望制药's product pipeline addresses a wide range of indications, including cardiovascular diseases, rare diseases, viral infections, metabolic diseases, and central nervous system disorders [1] - Key products in clinical phase II include cardiovascular drugs BW-01 and BW-02, rare disease drug PKK, and hepatitis B drug HBV [1] Investment Background - 舶望制药 has undergone several rounds of financing, with investors including 杏泽资本, 正心谷资本, CPE源峰, 道远资本, 三一创新投资, and 金沙江联合创投 [1]